日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Blood pressure is a beautiful (but imperfect) biomarker of hypertension. The quixotic quest that fuels the hypertension guideline industry

血压是高血压的一个很好(但并不完美)的生物标志物。高血压指南行业正进行着一场不切实际的探索。

Giles, Thomas D; Kostis, John B; Fernandez, Camilo

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data

奈必洛尔/缬沙坦联合治疗高血压的理论依据:临床前和临床数据回顾

Giles, Thomas D; Cockcroft, John R; Pitt, Bertram; Jakate, Abhijeet; Wright, Harold M

Analysis of decreases in systemic arterial pressure and heart rate in response to the hydrogen sulfide donor sodium sulfide

分析硫化氢供体硫化钠对全身动脉血压和心率下降的影响

Swan, Kevin W; Song, Bryant M; Chen, Allen L; Chen, Travis J; Chan, Ryan A; Guidry, Bradley T; Katakam, Prasad V G; Kerut, Edmund K; Giles, Thomas D; Kadowitz, Philip J

Digital plethysmography and arginine metabolism in prehypertension: effect of nebivolol therapy

数字容积描记法和精氨酸代谢在高血压前期患者中的作用:奈必洛尔治疗的影响

Kandavar, Ramprasad; Fernandez, Camilo; Sander, Gary E; Kim, Catherine; Velaga, Santhosh; Sukhanov, Sergiy; Delafontaine, Patrice; Egan, Peter; Roffidal, Louise E; Giles, Thomas D

Endothelial Progenitor Cells as a Biomarker for Transitional Phenotypes in Hypertension

内皮祖细胞作为高血压过渡表型的生物标志物

Giles, Thomas D; Sander, Gary E

Hypertension 101: the place to start

高血压入门知识:从哪里开始

Giles, Thomas D

Vascular stiffness is a biomarker of global cardiovascular risk

血管僵硬是全球心血管风险的生物标志物。

Sander, Gary E; Giles, Thomas D

Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial

奈必洛尔单药治疗年轻成人(小于 55 岁)高血压:一项随机、安慰剂对照试验

Giles, Thomas D; Khan, Bobby V; Lato, June; Brener, Lillian; Ma, Yimin; Lukic, Tatjana

Diastolic blood pressure and hypertension phenotypes: the US Food and Drug Administration has it right

舒张压和高血压表型:美国食品药品监督管理局的说法是正确的

Giles, Thomas D; Sander, Gary E

Inter-arm difference in systolic blood pressure-"the plot stiffens"-

双臂收缩压差异——“曲线趋于平缓”——

Giles, Thomas D